CREBBP and neoplasm: The oral Compound E7386 selectively inhibited the interaction of β-catenin with the β-catenin transcriptional coactivator CREB-binding protein (CBP) and exerted high antitumor activity in a human gastric cancer xenograft tumor model (94).